Quark Begins Patient Dosing in Phase I Study of Ocular Neuroprotectant | GenomeWeb

Quark Pharmaceuticals said this week that it has dosed the first patient in a phase I study of its siRNA-based ocular neuroprotectant QPI-1007.

In the study, the drug will be directly delivered to the eyes of legally blind patients and patients with a recent onset of non-arteritic anterior ischemic optic neuropathy, a rare condition that can lead to permanent blindness. Primary endpoints of the trial are safety and tolerability, but Quark will also evaluate whether QPI-1007 has any biological activity in NAION patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.